Education
About Us
Working with TipRanks
Follow Us
Medline, Inc. Class A (MDLN)
NASDAQ:MDLN
MDLN Analyst Ratings
Strong Buy
22 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MDLN Stock 12 Month Forecast
Average Price Target
$47.24
▲(8.82% Upside)
| Highest Price Target$52.00 | Average Price Target$47.24 | Lowest Price Target$38.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
$48
Buy
10.57%
Upside
Initiated
01/13/26
J.P. Morgan
$50
Buy
15.18%
Upside
Initiated
01/12/26
Robert W. Baird
$48
Buy
10.57%
Upside
Initiated
01/12/26
Deutsche Bank
$40
Hold
-7.86%
Downside
Initiated
01/12/26
Barclays
$50
Buy
15.18%
Upside
Initiated
01/12/26
Wolfe Research
$47
Buy
8.27%
Upside
Initiated
01/12/26
TD Cowen
$46
Buy
5.97%
Upside
Initiated
01/12/26
We initiate coverage of Medline Industries (MDLN) with a BUY rating and $46 PT. We believe Medline, the leading med-surg distributor/manufacturer, can continue to take market share, see margin expansion from conversion to branded products, and grow from M&A/entering new markets. Tariffs are a large but manageable risk. Our PT implies share can trade at 19x our CY27 adj. EBITDA est.
UBS
$48
Buy
10.57%
Upside
Initiated
01/12/26
William Blair
Buy
―
Initiated
01/12/26
Exane BNP Paribas
$38
Hold
-12.46%
Downside
Initiated
01/12/26
Rothschild & Co Redburn
$42
Hold
-3.25%
Downside
Initiated
01/12/26
Stifel Nicolaus
$46
Buy
5.97%
Upside
Initiated
01/12/26
Mizuho Securities
$48
Buy
10.57%
Upside
Initiated
01/12/26
We initiate coverage of Outperform rating and $48 PT. From a headline perspective, we believe a primary reason to invest in MDLN is that the company’s hybrid manufacturing and wholesale distribution approach to the Medical-Surgical Supply market has led to large market share gains for Medline over the past 10+ years from other publicly traded companies in our Healthcare Distribution sector coverage universe, and we believe Medline is only in the "middle innings" of this playbook, suggesting another decade or more of potential above-industry-average growth opportunity. This growth outlook is reinforced by the company's successful Prime Vendor customer strategy (more below). Our $48 PT is based on an ~18x EBITDA multiple of our 2027 forecast. With ~20% upside from current levels, we initiate with an Outperform rating.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
$48
Buy
10.57%
Upside
Initiated
01/13/26
J.P. Morgan
$50
Buy
15.18%
Upside
Initiated
01/12/26
Robert W. Baird
$48
Buy
10.57%
Upside
Initiated
01/12/26
Deutsche Bank
$40
Hold
-7.86%
Downside
Initiated
01/12/26
Barclays
$50
Buy
15.18%
Upside
Initiated
01/12/26
Wolfe Research
$47
Buy
8.27%
Upside
Initiated
01/12/26
TD Cowen
$46
Buy
5.97%
Upside
Initiated
01/12/26
We initiate coverage of Medline Industries (MDLN) with a BUY rating and $46 PT. We believe Medline, the leading med-surg distributor/manufacturer, can continue to take market share, see margin expansion from conversion to branded products, and grow from M&A/entering new markets. Tariffs are a large but manageable risk. Our PT implies share can trade at 19x our CY27 adj. EBITDA est.
UBS
$48
Buy
10.57%
Upside
Initiated
01/12/26
William Blair
Buy
―
Initiated
01/12/26
Exane BNP Paribas
$38
Hold
-12.46%
Downside
Initiated
01/12/26
Rothschild & Co Redburn
$42
Hold
-3.25%
Downside
Initiated
01/12/26
Stifel Nicolaus
$46
Buy
5.97%
Upside
Initiated
01/12/26
Mizuho Securities
$48
Buy
10.57%
Upside
Initiated
01/12/26
We initiate coverage of Outperform rating and $48 PT. From a headline perspective, we believe a primary reason to invest in MDLN is that the company’s hybrid manufacturing and wholesale distribution approach to the Medical-Surgical Supply market has led to large market share gains for Medline over the past 10+ years from other publicly traded companies in our Healthcare Distribution sector coverage universe, and we believe Medline is only in the "middle innings" of this playbook, suggesting another decade or more of potential above-industry-average growth opportunity. This growth outlook is reinforced by the company's successful Prime Vendor customer strategy (more below). Our $48 PT is based on an ~18x EBITDA multiple of our 2027 forecast. With ~20% upside from current levels, we initiate with an Outperform rating.
Best Analysts Covering Medline, Inc. Class A
3 Months
xxx
Success Rate
1/1 ratings generated profit
Average Return
+5.40%
initiated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +5.40% per trade.
1 Year
Success Rate
1/1 ratings generated profit
Average Return
+5.40%
initiated a buy rating 5 days ago
Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +5.40% per trade.
2 Years
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
initiated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MDLN Analyst Recommendation Trends
Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
22
Hold
0
0
0
0
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
0
26
Each month's total comprises the sum of three months' worth of ratings.
MDLN Financial Forecast
MDLN Stock Forecast FAQ
What is MDLN’s average 12-month price target, according to analysts?
Based on analyst ratings, Medline, Inc. Class A’s 12-month average price target is 47.24.
What is MDLN’s upside potential, based on the analysts’ average price target?
Medline, Inc. Class A has 8.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MDLN a Buy, Sell or Hold?
Medline, Inc. Class A has a consensus rating of Strong Buy which is based on 22 buy ratings, 4 hold ratings and 0 sell ratings.
What is Medline, Inc. Class A’s price target?
The average price target for Medline, Inc. Class A is 47.24. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $38.00. The average price target represents 8.82% Increase from the current price of $43.41.
The highest analyst price target is $52.00 ,the lowest forecast is $38.00. The average price target represents 8.82% Increase from the current price of $43.41.
What do analysts say about Medline, Inc. Class A?
Medline, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 26 Wall Streets Analysts.
How can I buy shares of MDLN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.